Arrhythmia Research Technology (HRT) Swings to Q4 Profit

Arrhythmia Research Technology (NYSE: HRT) reported Q4 EPS of $0.01, versus ($0.03) reported last year. Revenue for the quarter came in at $5.7 million, versus $6.1 million reported last year.

Adjusted EBITDA(1) (income from continuing operations adjusted for income taxes, other income and expense, interest, depreciation and amortization, and share-based compensation expense) for the fourth quarter of 2014 was $471 thousand, or 8.2% of net sales, compared with $402 thousand, or 6.6% of net sales, for the same period of the prior year.

For earnings history and earnings-related data on Arrhythmia Research Technology (HRT) click here.

You May Also Be Interested In

• Klarna shares tumble on weak full-year revenue guidance
• Halozyme adds biotech executive Appelhans to its board
• La-Z-Boy (LZB) Misses Q1 EPS by 6c, Misses on Revenue; Offers Weak Q2 Revenue Guidance